Literature DB >> 12898284

Evaluation of the Merlin, Micronaut system for automated antimicrobial susceptibility testing of Pseudomonas aeruginosa and Burkholderia species isolated from cystic fibrosis patients.

S Häussler1, S Ziesing, G Rademacher, L Hoy, H Weissbrodt.   

Abstract

Since accurate antimicrobial susceptibility testing of bacterial cystic fibrosis isolates is known to be problematic and an optimal in vitro testing method has not yet been evaluated, the study presented here was conducted to compare the performance of the reference agar dilution method and broth microdilution with a commercially available automated susceptibility test system (Merlin; Micronaut, Germany). In this pilot study, the susceptibility of 70 clinical strains of Pseudomonas aeruginosa and Burkholderia cepacia-like organisms to nine antimicrobial agents was tested using these methods. Susceptibility results generated by broth microdilution (both automated and according to the National Committee for Clinical Laboratory Standards recommendations) were demonstrated to be of good reproducibility, and they compared favourably to the time- and material-consuming standard agar dilution reference method, especially after a prolonged incubation time (48 h).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12898284     DOI: 10.1007/s10096-003-0974-7

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  11 in total

1.  Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; J Krzewinski; Z Liu; D Larone; S A Marshall; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2001-04       Impact factor: 2.803

2.  Fatal outcome of lung transplantation in cystic fibrosis patients due to small-colony variants of the Burkholderia cepacia complex.

Authors:  S Häussler; C Lehmann; C Breselge; M Rohde; M Classen; B Tümmler; P Vandamme; I Steinmetz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-03-28       Impact factor: 3.267

3.  Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.

Authors:  L Saiman; F Mehar; W W Niu; H C Neu; K J Shaw; G Miller; A Prince
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

4.  Small-colony variants of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  S Häussler; B Tümmler; H Weissbrodt; M Rohde; I Steinmetz
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

5.  Evaluation of reference dilution test methods for antimicrobial susceptibility testing of Pseudomonas aeruginosa strains isolated from patients with cystic fibrosis.

Authors:  L Saiman; J L Burns; S Whittier; J Krzewinski; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

6.  Comparison of agar diffusion methodologies for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  J L Burns; L Saiman; S Whittier; D Larone; J Krzewinski; Z Liu; S A Marshall; R N Jones
Journal:  J Clin Microbiol       Date:  2000-05       Impact factor: 5.948

7.  Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function.

Authors:  M Hentzer; G M Teitzel; G J Balzer; A Heydorn; S Molin; M Givskov; M R Parsek
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

Review 8.  Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia.

Authors:  J R Govan; V Deretic
Journal:  Microbiol Rev       Date:  1996-09

9.  Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa.

Authors:  G L Morlin; D L Hedges; A L Smith; J L Burns
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

Review 10.  Lung infections associated with cystic fibrosis.

Authors:  Jeffrey B Lyczak; Carolyn L Cannon; Gerald B Pier
Journal:  Clin Microbiol Rev       Date:  2002-04       Impact factor: 26.132

View more
  5 in total

1.  Evaluation of the Merlin MICRONAUT system for rapid direct susceptibility testing of gram-positive cocci and gram-negative bacilli from positive blood cultures.

Authors:  Nele Wellinghausen; Tim Pietzcker; Sven Poppert; Syron Belak; Nicole Fieser; Melanie Bartel; Andreas Essig
Journal:  J Clin Microbiol       Date:  2007-01-03       Impact factor: 5.948

2.  Comparison of the Micronaut Merlin automated broth microtiter system with the standard agar dilution method for antimicrobial susceptibility testing of mucoid and nonmucoid Pseudomonas aeruginosa isolates from cystic fibrosis patients.

Authors:  B Balke; L Hoy; H Weissbrodt; S Häussler
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-10       Impact factor: 3.267

3.  Molecular epidemiology of Pseudomonas aeruginosa in cystic fibrosis patients from Southeast Austria.

Authors:  Lilian Masoud-Landgraf; Alexandra Badura; Ernst Eber; Gebhard Feierl; Josefa Posch; Gernot Zarfel; Maximilian Zach; Egon Marth
Journal:  Wien Klin Wochenschr       Date:  2012-04-21       Impact factor: 1.704

4.  The importance of growth kinetic analysis in determining bacterial susceptibility against antibiotics and silver nanoparticles.

Authors:  Karsten Theophel; Veronika J Schacht; Michael Schlüter; Sylvia Schnell; Catalina-Suzana Stingu; Reiner Schaumann; Michael Bunge
Journal:  Front Microbiol       Date:  2014-11-10       Impact factor: 5.640

5.  Analysis and Characterization of Staphylococcus aureus Small Colony Variants Isolated From Cystic Fibrosis Patients in Austria.

Authors:  Lilian Masoud-Landgraf; Gernot Zarfel; Tanja Kaschnigg; Simone Friedl; Gebhard Feierl; Ute Wagner-Eibel; Ernst Eber; Andrea J Grisold; Clemens Kittinger
Journal:  Curr Microbiol       Date:  2016-01-28       Impact factor: 2.188

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.